Sign In
Buy RYTM
$99.25
-6.49 (-6.14%)
At Close: Jul 31, 2026
Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
08:00am, Thursday, 09'th Apr 2026
BOSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ra
SG Americas Securities LLC Lowers Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTM
04:47am, Wednesday, 08'th Apr 2026
SG Americas Securities LLC reduced its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) by 40.0% in the undefined quarter, according to the company in its most recent disclosure with
Rhythm Pharmaceuticals Announces Changes to Board of Directors
09:00am, Friday, 03'rd Apr 2026
-- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical c
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength?
09:10am, Wednesday, 01'st Apr 2026
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the
Is This Weight Loss Drug Stock a Buy After a New Approval?
04:00pm, Tuesday, 31'st Mar 2026
This little-known biotech company has a different strategy than the established weight-loss drug market leaders. But is it likely to be successful?
-- European Commission decision anticipated in second quarter of 2026 -- BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceut
Rhythm Pharmaceuticals EMANATE Phase 3 Misses Primary Endpoint, Sees Subgroup Signals for Setmelanotide
02:04am, Sunday, 22'nd Mar 2026
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Phase 3 top-line results from its EMANATE trial evaluating setmelanotide in four heterozygous genetic cohorts linked to MC4R pathway dysfunction, with co
PITTSBURGH, March 20, 2026 /PRNewswire/ -- PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, announced that it was
Rhythm Surges On A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat'
09:23am, Friday, 20'th Mar 2026
Rhythm Pharmaceuticals stock popped Friday after the FDA signed off on its obesity drug for patients with a rare, hunger-spiking disease.
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity Transcript
03:32am, Friday, 20'th Mar 2026
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity Transcript
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
06:30pm, Thursday, 19'th Mar 2026
-- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfun
U.S. stock futures tumbled on Tuesday following Monday's advances. Futures of the major benchmark indices were lower.
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Topline Results and Insights from Phase 3 EMANATE Trial Transcript
02:02am, Tuesday, 17'th Mar 2026
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Topline Results and Insights from Phase 3 EMANATE Trial Transcript
Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial
04:07pm, Monday, 16'th Mar 2026
Rhythm Pharmaceuticals said on Monday its experimental obesity drug in patients with rare genetic conditions did not meet the main goal of a late-stage trial.
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
04:01pm, Monday, 16'th Mar 2026
-- Four substudies did not meet pre-specified primary endpoints -- -- Post hoc analyses show setmelanotide achieved statistically significant BMI reductions in patients with obesity due to a heteroz
